Royalty Pharma plc — Director's Dealing 2022

Mar 21, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Royalty Pharma plc (RPRX)
CIK: 0001802768
Period of Report: 2022-03-17

Reporting Person: RIGGS RORY B (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-03-17	Class A Ordinary Shares	J	4897	—	Acquired	597645	Direct
2022-03-17	Class A Ordinary Shares	J	64067	—	Acquired	661712	Direct
2022-03-17	Class A Ordinary Shares	J	229626	—	Disposed	72348	Indirect
2022-03-17	Class A Ordinary Shares	J	1075178	—	Disposed	40560	Indirect
2022-03-17	Class A Ordinary Shares	J	531684	—	Disposed	141368	Indirect
2022-03-18	Class A Ordinary Shares	S	46803	$39.3831	Disposed	25545	Indirect
2022-03-18	Class A Ordinary Shares	S	26238	$39.3831	Disposed	14322	Indirect
2022-03-18	Class A Ordinary Shares	S	56181	$39.766	Disposed	85187	Indirect
2022-03-21	Class A Ordinary Shares	S	25545	$39.051	Disposed	0	Indirect
2022-03-21	Class A Ordinary Shares	S	14322	$39.051	Disposed	0	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Class A Ordinary Shares	15000	Indirect

Footnotes

F1: Pro rata distribution from New Ventures Select, of which the Reporting Person has voting and investment control.

F2: Pro rata distribution from a limited liability company of which the Reporting Person is a member.

F3: Pro rata distribution from New Ventures I LLC, of which the Reporting Person has voting and investment control.

F4: New Ventures Select distributed these shares to its members on a pro rata basis, for no consideration.

F5: New Ventures I LLC distributed these shares to its members on a pro rata basis, for no consideration.

F6: New Ventures III LLC distributed these shares to its members on a pro rata basis, for no consideration.

F7: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.20 to $39.70 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F8: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.21 to $39.71 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F9: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.71 to $39.30 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.